Teva Pharmaceutical Industries (NYSE:TEVA) VP Sells $3,311,622.24 in Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) VP Richard Daniell sold 115,468 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the completion of the sale, the vice president owned 48,384 shares in the company, valued at $1,387,653.12. The trade was a 70.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Teva Pharmaceutical Industries Trading Down 1.3%

Shares of NYSE:TEVA opened at $29.80 on Friday. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.82 and a current ratio of 1.11. The stock has a market capitalization of $34.18 billion, a price-to-earnings ratio of 49.67, a PEG ratio of 1.77 and a beta of 0.67. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $30.20. The company has a 50 day moving average price of $23.43 and a 200 day moving average price of $19.62.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Phoenix Financial Ltd. lifted its position in Teva Pharmaceutical Industries by 9.4% during the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after purchasing an additional 3,533,800 shares during the period. Ion Asset Management Ltd. grew its position in shares of Teva Pharmaceutical Industries by 6.5% during the 1st quarter. Ion Asset Management Ltd. now owns 39,033,500 shares of the company’s stock worth $599,945,000 after buying an additional 2,383,500 shares during the period. Menora Mivtachim Holdings LTD. increased its stake in shares of Teva Pharmaceutical Industries by 1.1% in the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company’s stock valued at $786,190,000 after acquiring an additional 427,000 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its position in shares of Teva Pharmaceutical Industries by 12.9% in the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock valued at $761,455,000 after acquiring an additional 4,306,363 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. raised its position in shares of Teva Pharmaceutical Industries by 13.6% in the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 32,582,212 shares of the company’s stock valued at $658,161,000 after acquiring an additional 3,896,790 shares during the period. 54.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on TEVA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. Wall Street Zen cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Saturday. The Goldman Sachs Group boosted their price objective on Teva Pharmaceutical Industries from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Bank of America raised their target price on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Finally, Scotiabank started coverage on shares of Teva Pharmaceutical Industries in a report on Friday, December 5th. They set a “sector outperform” rating and a $35.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of “Buy” and an average target price of $30.25.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.